JUMP REPORT
| Avg Daily Volume: 8,715,002 Market Cap: 126.54B Sector: Technology Short Interest: 1.64 |
EARNINGS EXPECTATIONS:
THIS QTR: EPS: 1.58/share REV: 2,920/M
___________________________________________________________
LAST QTR: EPS: 1.14/share ACTUAL: 1.24/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.70/share REV: 3,060/M
______________________________________________________
FULL YR: EPS: 5.40/share REV: 10,780/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
______________________________________________________
BEAT/MISS RECORD: 52% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 8.58, -3.27, 6.09
EXPECTED JUMP MOVE: 8-10%
Links To Latest News and Headlines
Nvidia’s data-center sales are expected to edge out gaming results as demand from server farms is high but gaming has softened from peak COVID-19 levels.
In less than week — Wednesday, May 25 — Nvidia (NVDA) is due to report its Q1 2022 earnings. Analysts on average are optimistic about the report itself, and also about the guidance Nvidia might give, predicting Nvidia will report 43% growth to $1.30 per share this quarter, and promise investors another 31% worth of growth ($1.36 per share) next quarter. And one analyst thinks Nvidia could do even better than that. Previewing next Wednesday’s earnings report, Oppenheimer’s Rick Schafer reiterat
Shares of Nvidia (NASDAQ: NVDA) continued to tumble on Friday, falling as much as 8%. Wells Fargo analyst Aaron Rakers lowered his price target on Nvidia to $250, down from $370, while maintaining his overweight (buy) rating on the stock, according to The Fly.
In this article, we discuss 10 buy-the-dip stocks to buy according to billionaire Ken Fisher. If you want to skip our detailed analysis of Fisher’s stock selection and the current sell-off in tech, go directly to 5 Best Buy-the-Dip Tech Stocks According to Billionaire Ken Fisher. The tech-heavy Nasdaq Composite is down 27% in 2022 […]
In reality, however, it seems bigger companies are able to grow more than smaller ones, perhaps leveraging their size (and deep pockets) to keep would-be competition in check. With that as the backdrop, here’s a closer look at three stocks that will likely display the market’s biggest market caps come 2030, from smallest to largest.
StockJumpers analysis and trade plans are uploaded generally 1 HOUR (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is striped down to only what it needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.